Healthcare · 13.1

Pharmaceuticals

Quantified news impact based on deduplicated, quality-reviewed events in a single 60-day window.

Average net impact+23weighted per event

Average gross impact28absolute weighted average

Events25same period

Confidence81%model average

Raw intensity60before weighting

Previous period0net impact

Gross changeInsufficient base

Diffusion speed0.4 / day

Concentration5%

Direction disagreement18%

Source independence98%14 sources

IMPACT TREND

60-day effective impact

Positive 21 · Negative 2 · Mixed 2

+250-25

5 Jun0 events

10 Jun0 events

15 Jun0 events

20 Jun0 events

25 Jun0 events

30 Jun0 events

5 Jul0 events

10 Jul0 events

15 Jul0 events

20 Jul0 events

+23

25 Jul19 events

+25

30 Jul6 events

Current periodPrevious period

TIME HORIZON

Impact duration

Immediate0%0 cumulative effective impact

Short term47%331 cumulative effective impact

Medium term47%333 cumulative effective impact

Long term7%47 cumulative effective impact

CO-IMPACT

Related industries

EVENT EVIDENCE

Events ranked by effective impact

Page 3 of 3 · 25 events

Macro1

Macro27 Jul, 16:51positive

Hong Kong Q2 2026 Ad Spend Rises 5% to HK$8.77 Billion, World Cup Boosts June by 9%

Hong Kong's advertising expenditure in the second quarter of 2026 reached HK$8.77 billion, up 5% year-on-year. Monthly growth was 5% in April, 2% in May and 9% in June, driven by the World Cup. Social media led ad spending, followed by TV, mobile, search engine marketing and outdoor advertising. Magazine ads rose 22%. The banking, credit card and investment services sector saw a 19% increase, with HSBC and Hang Seng Bank posting 15% and 52% growth respectively. Insurance jumped 56% from 13th to 8th place.

Effective: +15
Intensity: 40
Confidence: 70%
Horizon: Short term

Industries2

Industries28 Jul, 19:26mixed

15 Pharma Firms in 2026 Fortune 500; Eli Lilly Jumps to 224th as Tirzepatide Tops Global Drug Sales

The 2026 Fortune Global 500 lists 15 pharmaceutical companies, unchanged from 2025 but with reshuffled rankings. Eli Lilly posted the largest leap, rising 112 spots to 224th, with revenue surging 44.7% to $65.179 billion and profit soaring 94.9% to $20.64 billion. Its GLP-1 drug tirzepatide generated $36.507 billion in sales, surpassing Novo Nordisk's semaglutide ($36.1 billion) to become the world's best-selling medicine. Novo Nordisk also gained 35 places, and both companies led profit margins among pharma peers.

Effective: 0
Intensity: 80
Confidence: 90%
Horizon: Medium term

Industries27 Jul, 09:22mixed

China's 12th Batch Drug Central Procurement Covers 65 Varieties, Introduces 'Volume-Less' Win and Reference

China's 12th batch of national centralized drug procurement has been launched, covering 65 varieties across therapeutic areas including hypertension, diabetes, oncology, organ transplant anti-rejection, and anti-infectives. The new rules introduce a 'volume-less' winning mechanism that uses statistical standard deviation to prevent extreme low pricing, and a separate channel for reference preparations that allows winning without volume commitment. Reporting by drug brand is now fully implemented, with 45,000 medical institutions and over 500 companies participating. The most competitive variety has more than 50 bidders.

Effective: 0
Intensity: 60
Confidence: 80%
Horizon: Short term

Companies2

Companies3 Aug, 16:31positive

Fosun Pharma Gets NMPA Approval for Two Drug Applications, Covering Diabetes and Childhood Constipation

On August 3, 2026, Fosun Pharma announced that its controlling subsidiary Fosun Wanbang (Jiangsu) Pharmaceutical Group received NMPA approval for empagliflozin and metformin hydrochloride extended-release tablets (III). The approved indication is to improve glycemic control in adults with type 2 diabetes already treated with these two drugs, in combination with diet and exercise. Another controlling subsidiary, Suzhou Erye Pharmaceutical, received approval for compound polyethylene glycol (3350) electrolyte powder to treat chronic constipation in children aged 1-11 and fecal impaction in children aged 5-11.

Effective: +14
Intensity: 30
Confidence: 80%
Horizon: Short term

Companies29 Jul, 18:53positive

Anke Bio's Wholly-Owned Unit Suhao Yiming Gets NMPA Approval for Terlipressin Acetate API

Anke Bio's wholly-owned sub-subsidiary, Shanghai Suhao Yiming Pharmaceutical Co. , Ltd. , received on July 29 the Chemical API Marketing Application Approval Notice from China's National Medical Products Administration for terlipressin acetate. The active pharmaceutical ingredient will be used to produce terlipressin preparations, which are indicated for gastrointestinal bleeding, genitourinary bleeding, postoperative bleeding, and hepatorenal syndrome.

Effective: +11
Intensity: 40
Confidence: 70%
Horizon: Short term